LLY
Eli Lilly & Co.
Latest price
As of Oct 26, 2026, 6:30 PM EDT · Market data by Massive
Market cap
$1.1T
Volume
2.1M
Previous close
$1,273.46
Day range
$1,273.73 – $1,296.90
Listed
Jul 9, 1970
Coverage
11 articles
Price performance
Recent trading
Newsroom
Latest LLY coverage
Eli Lilly Stock Climbs as GLP-1 Demand Fuels Higher Sales Outlook
Eli Lilly (LLY) shares surged on Wednesday after the pharmaceutical giant raised its full-year sales forecast and delivered second-quarter results that beat expectations.
Eli Lilly Expands Its Neuroscience Pipeline With Major Depression Therapy Bet
Eli Lilly (LLY) is making another significant push beyond its blockbuster diabetes and obesity franchises, announcing an agreement to acquire clinical-stage biotech AtaiBeckley in a deal valued at up to $3.8 billion.
Stock Market Today: Dow Climbs as S&P 500, Nasdaq Slide With AI Fears in Focus Ahead of Google Earnings
U.S. stocks traded mixed on Wednesday as investors rotated out of technology and into blue-chip names while awaiting another wave of Big Tech earnings.
Nektar Therapeutics Gains New Life On Buyout Rumors & Atopic Dermatitis Breakthrough
Nektar Therapeutics rises after reports of Eli Lilly’s buyout interest and strong Phase IIb results for REZPEG. With FDA Fast Track status and solid cash reserves, investor optimism builds.
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here's Why Zepbound Already Has a Giant Lead
Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the pharma giant is preparing for its next leap: a daily oral pill named orforglipron.
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused on one-time therapies to lower cholesterol and prevent heart disease.
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?
Eli Lilly has agreed to acquire SiteOne Therapeutics, a clinical-stage biotech specializing in small molecule inhibitors of sodium channels involved in pain signal transmission.
Stock Market Today: Dow Plunges Over 500 Points as UnitedHealth Tanks; S&P and Nasdaq End Flat
Stocks wrapped a volatile shortened trading week with mixed performances on Thursday as a sharp sell-off in UnitedHealth dragged the Dow deep into the red.
Altimmune’s Strategic Moves Spark M&A Buzz: Is It The Hottest Player In Obesity & Liver Disease?
Altimmune's recent success on the FDA front escalated when a Betaville "uncooked" alert suggested that the company may be undergoing a strategic review involving at least three large pharma companies.
Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!
According to a Betaville "uncooked" alert, an unidentified European pharmaceutical company is reportedly exploring a bid for Arcutis Biotherapeutics.
Stock Market Today: Stocks Stage Comeback After Positive Labor Market Data
The major U.S. indices reversed course on Thursday, clawing back from recent losses after positive labor market data calmed investor anxieties. As of midday trading, the S&P 500 was up 1.92%, while the Nasdaq surged 2.32%, and the Dow Jones Industrial Average climbed to 1.43%.